 NEW HAVEN, Conn., Sept. 26, 2022 GLOBE NEWSWIRE -- Arvinas, Inc. Nasdaq: ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities Precision Oncology Conference taking place virtually on Monday, October 3 at 10:40 a.m. ET. 